Clinical Trials Browser

INDUSTRY × Interventional × Other hematologic neoplasm × Clear all

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05294731 2026-04-17

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05429632 2026-04-17

MO-TRANS

Phase 3 Recruiting

366 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05475925 2026-04-17

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

Phase 1/2 Recruiting

200 enrolled

DermatologicLymphoidOther hematologic neoplasm

Subcutaneous panniculitis-like T-cell lymphoma, Leukemia, Lymphoma, Leukemia, Large Granular Lymphocytic, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT05607199 2026-04-17

BHARAT-1

Phase 1 Terminated

27 enrolled

LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06427811 2026-04-17

ASC4INDIA

Phase 4 Completed

85 enrolled

MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Clinical Trials

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

MO-TRANS

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

BHARAT-1

ASC4INDIA

VIJAY-1

Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

MB-dNPM1-TCR.1 in Relapsed/Refractory AML

A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia

CaDAnCe-302

QUATRO-APL

OPAL

CaDAnCe-101

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

A Study of BGB-11417 in Participants With Myeloid Malignancies

cAMeLot-1

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Safety and Tolerability of ZE74-0282 in Healthy Volunteers

CAN3001

A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations

MajesTEC-1

MonumenTAL-1

GLOW

MK-3475-587

MajesTEC-1

EPCORE™ CLL-1

MonumenTAL-1

A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma

MK-1026-003

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

EXCELL

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

TAILOR